Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index

Type 1 Diabetes Mellitus Clinical Trial

Official title:

Feasibility Evaluation of an Artificial Pancreas With an Enhanced Model Predictive Control (eMPC) Controller and a Health Monitoring System (HMS) With a Glucose Prediction Trust Index

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03092310
• Other study ID #: Pro00020556
• Status: Completed
• Phase: N/A
• Start date: March 20, 2017
• Est. completion date: December 20, 2017

Study information

• Verified date: July 2018
• Source: Sansum Diabetes Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this pilot study is to establish that closed-loop insulin delivery with a target enchanted model predictive control (eMPC)/Health Monitoring System (HMS) algorithms with a trust index of the predicted glucose value is safe and effective, to analyze and learn to improve upon the accuracy of the predicted glucose values, and to collect efficacy data to inform a future larger study.

Description:

This is a feasibility study of an artificial pancreas (AP) system with our previously validated target eMPC and HMS algorithms, with the addition of a trust index of the predicted glucose value integrated into the portable Artificial Pancreas System (pAPS). The system will be evaluated on up to 20 subjects, with the goal of 10 subjects completing a 48-hour closed-loop session at one clinical site (William Sansum Diabetes Center). During the session subjects will bolus for all meals and snacks and perform a 45-minute walking session.

The purpose of this pilot study is to establish that closed-loop insulin delivery with a target enchanted model predictive control (eMPC)/Health Monitoring System (HMS) algorithms with a trust index of the predicted glucose value is safe and effective, to analyze and learn to improve upon the accuracy of the predicted glucose values, and to collect efficacy data to inform a future larger study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: December 20, 2017
• Est. primary completion date: December 20, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age = 18 and = 75 years at the time of screening.

• Clinical diagnosis of type 1 diabetes for at least one year.

• Has been using an insulin pump for at least 6 months at the time of screening.

• HbA1c < 10%, as performed by point of care or central laboratory testing. A1c will be assessed at the screening visit, or if already completed within 2 months of the screening visit, the prior lab value may be used in lieu of repeating this assessment.

• Serum creatinine of < 2.0 mg/dL. Serum creatinine will be assessed at the screening visit, or if already completed within 2 months of the screening visit, the prior lab value may be used in lieu of repeating this assessment.

• Bolus for all meals and snacks that contain = 5 grams of carbohydrate.

• Willing to perform at least 7 fingerstick blood glucose tests a day.

• Willing to refrain from taking acetaminophen products for the duration of the clinical trial. If acetaminophen is taken, subject is to avoid making any insulin dosing decisions based on CGM for at least 12 hours.

• Willing to abide by the study protocol and use study-provided devices, including the Omnipod, Dexcom CGM, glucometer, ketone meter and pAPS tablet.

Exclusion Criteria:

• Pregnancy

• One or more episodes of hypoglycemia requiring an emergency room visit or hospitalization in the past 6 months.

• One or more episodes of hyperglycemia requiring an emergency room visit or hospitalization in the past 6 months.

• Known unstable cardiac disease or untreated cardiac disease, as revealed by history or physical examination.

• Dermatological conditions that would preclude wearing a CGM sensor or Pod.

• One or more seizures in the past year.

• Screening A1c = 10% or serum creatinine = 2.0 mg/dL.

• Any condition that could interfere with participating in the trial, based on investigator judgment.

• Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals), defined as using any of these medications within 30 days of the screening visit or during the study.

• Participation in another pharmaceutical or device trial at the time of enrollment or during the study.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Device:
• Artificial Pancreas Device
Artificial Pancreas Device

Locations

Country	Name	City	State
United States	William Sansum Diabetes Center	Santa Barbara	California

Sponsors (2)

Lead Sponsor	Collaborator
Sansum Diabetes Research Institute	Harvard University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Pinsker JE, Laguna Sanz AJ, Lee JB, Church MM, Andre C, Lindsey LE, Doyle FJ 3rd, Dassau E. Evaluation of an Artificial Pancreas with Enhanced Model Predictive Control and a Glucose Prediction Trust Index with Unannounced Exercise. Diabetes Technol Ther. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent time within the target glucose range of 70-180 mg/dl overall as assessed by continuous glucose monitoring (CGM).	The primary endpoint for this pilot study will be time within the target glucose range of 70-180 mg/dl overall as assessed by continuous glucose monitoring (CGM), during closed-loop use, determining if the combination of eMPC and the assessment of trust index can provide safe and effective glucose control.	48 hours
Secondary	Assessment of the trust index predictions vs. standard eMPC glucose predictions.	During closed-loop use, assessment of the trust index predictions vs. standard eMPC glucose predictions (frequency of moving away from nominal weights of predicted glucose).	48 hours
Secondary	Frequency of hypoglycemia during closed-loop use.	Frequency of hypoglycemia during closed-loop use, defined as percent time glucose is below predefined thresholds of 70 mg/dl, 60 mg/dl and 50 mg/dL.	48 hours
Secondary	Frequency of hyperglycemia during closed-loop use.	Frequency of hyperglycemia during closed-loop use, defined as percent time glucose is above predefined thresholds of 180 mg/dl, 250 mg/dl, and 300 mg/dL.	48 hours
Secondary	Percent time within the target glucose range of 70-140 mg/dl during closed-loop use.	Percent time within the target glucose range of 70-140 mg/dl overall as assessed by continuous glucose monitoring (CGM), during closed-loop use.	48 hours
Secondary	Percent time glucose is within range 70-150 mg/dl postprandial within 5 hours following meals, during closed-loop use.	Percent time glucose is within range 70-150 mg/dl postprandial within 5 hours following meals, during closed-loop use.	48 hours
Secondary	Standard Deviation and Coefficient of Variation of glucose values	To measure glycemic variability, the standard deviation and coefficient of variation of glucose values (as measured by continuous glucose monitoring) will be determined during the 48 hours of closed-loop use.	48 hours
Secondary	Markers of hypo- and hyperglycemia	Markers of hypo- and hyperglycemia, to include LBGI (Low blood glucose index) and HBGI (High blood glucose index), during closed-loop use.	48 hours
Secondary	Insulin Doses Given	Change in total daily doses and post prandial insulin doses given during the 48 hours of closed-loop use.	48 hours
Secondary	Number of treatments given for hypoglycemia (defined as carbohydrates given for treatment of a documented or suspected low blood sugar), during the 48 hours of closed-loop use.	Treatments for hypoglycemia given during the 48 hours of closed-loop use. Hypoglycemia treatments may be given in response to alerts from the HMS, if blood glucose < 70 mg/dL, or at the request of the subject or investigator.	48 hours
Secondary	Number of alerts given by the HMS to prevent hypoglycemia	Number of alerts given by the HMS to prevent hypoglycemia during closed-loop use.	48 hours
Secondary	Failure analysis of the devices/connectivity issues that may occur (# disconnects and device restarts).	Failure analysis of the devices/connectivity issues that may occur during closed-loop use. This includes number of CGM communication losses with 3 or more missed points, and number of times the entire system required a restart.	48 hours